Peñas-LLedó EM - Search Results

1

Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Céspedes-Garro C, Naranjo MG, Rodrigues-Soares F, LLerena A, Duconge J, Montané-Jaime LK, Roblejo H, Fariñas H, Campos ML, Ramírez R, Serrano V, Villagrán CI, Peñas-LLedó EM. Céspedes-Garro C, et al. Among authors: penas lledo em. Pharmacogenomics. 2016 Oct;17(15):1707-1724. doi: 10.2217/pgs-2016-0053. Epub 2016 Sep 16. Pharmacogenomics. 2016. PMID: 27633613 Free PMC article. Review.

2

[Prevalence of polydipsia and water intoxication in psychiatric inpatients].

Llerena A, De la Rubia Martínez A, Peñas-Lledó EM. Llerena A, et al. Actas Esp Psiquiatr. 2001 Sep-Oct;29(5):299-303. Actas Esp Psiquiatr. 2001. PMID: 11602086 Spanish.

3

Schizophrenia stigma among medical and nursing undergraduates.

Llerena A, Cáceres MC, Peñas-LLedó EM. Llerena A, et al. Eur Psychiatry. 2002 Sep;17(5):298-9. doi: 10.1016/s0924-9338(02)00672-7. Eur Psychiatry. 2002. PMID: 12381503 No abstract available.

4

Schizophrenia and tobacco smoking in a Spanish psychiatric hospital.

LLerena A, de la Rubia A, Peñas-Lledó EM, Diaz FJ, de Leon J. LLerena A, et al. Schizophr Res. 2003 Apr 1;60(2-3):313-7. doi: 10.1016/s0920-9964(02)00508-x. Schizophr Res. 2003. PMID: 12591592

5

CYP2C9 gene and susceptibility to major depressive disorder.

LLerena A, Berecz R, Dorado P, González AP, Peñas-LLedó EM, De La Rubia A. LLerena A, et al. Pharmacogenomics J. 2003;3(5):300-2. doi: 10.1038/sj.tpj.6500197. Pharmacogenomics J. 2003. PMID: 14583800

6

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

LLerena A, Dorado P, Berecz R, González AP, Peñas-LLedó EM. LLerena A, et al. Eur J Clin Pharmacol. 2004 Feb;59(12):869-73. doi: 10.1007/s00228-003-0707-y. Epub 2004 Jan 16. Eur J Clin Pharmacol. 2004. PMID: 14726986 Clinical Trial.

7

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.

Dorado P, Berecz R, Peñas-Lledó EM, Cáceres MC, Llerena A. Dorado P, et al. Curr Drug Targets. 2006 Dec;7(12):1671-80. doi: 10.2174/138945006779025329. Curr Drug Targets. 2006. PMID: 17168842 Review.

8

Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.

Dorado P, Berecz R, Peñas-Lledó EM, Llerena A. Dorado P, et al. Expert Opin Drug Metab Toxicol. 2007 Feb;3(1):9-19. doi: 10.1517/17425255.3.1.9. Expert Opin Drug Metab Toxicol. 2007. PMID: 17269891 Review.

9

Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.

Llerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A. Llerena A, et al. Pharmacogenomics J. 2007 Dec;7(6):408-10. doi: 10.1038/sj.tpj.6500439. Epub 2007 Feb 27. Pharmacogenomics J. 2007. PMID: 17325735

10

Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.

Peñas-Lledó EM, Dorado P, Cáceres MC, de la Rubia A, Llerena A. Peñas-Lledó EM, et al. Clin Chem Lab Med. 2007;45(7):835-8. doi: 10.1515/CCLM.2007.181. Clin Chem Lab Med. 2007. PMID: 17617023

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters